PureTech Health plc (PTCHF)
USD 1.75
(-5.91%)
USD 1.75
(-5.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -167.19 Million USD | -62.34% |
| 2022 | -102.99 Million USD | 75.1% |
| 2021 | -413.68 Million USD | -26.41% |
| 2020 | -327.25 Million USD | -251.66% |
| 2019 | -93.06 Million USD | 11.1% |
| 2018 | -104.68 Million USD | -60.57% |
| 2017 | -65.19 Million USD | -16.41% |
| 2016 | -56 Million USD | 56.85% |
| 2015 | -129.79 Million USD | 38.78% |
| 2014 | -212.01 Million USD | -7180.63% |
| 2013 | -2.91 Million USD | 69.01% |
| 2012 | -9.39 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -183.74 Million USD | 10.88% |
| 2024 Q1 | -183.74 Million USD | -9.89% |
| 2023 Q1 | -224.43 Million USD | -117.91% |
| 2023 Q3 | -58.97 Million USD | 81.85% |
| 2023 Q2 | -324.93 Million USD | -44.78% |
| 2023 FY | -167.19 Million USD | -62.34% |
| 2023 Q4 | -167.19 Million USD | -183.51% |
| 2022 Q1 | -322.44 Million USD | 22.05% |
| 2022 Q2 | -317.81 Million USD | 1.44% |
| 2022 FY | -102.99 Million USD | 75.1% |
| 2022 Q3 | -107.96 Million USD | 66.03% |
| 2022 Q4 | -102.99 Million USD | 4.61% |
| 2021 FY | -413.68 Million USD | -26.41% |
| 2021 Q2 | -362.17 Million USD | 0.95% |
| 2021 Q3 | -416.9 Million USD | -15.11% |
| 2021 Q1 | -365.63 Million USD | -11.73% |
| 2021 Q4 | -413.68 Million USD | 0.77% |
| 2020 Q1 | -304.73 Million USD | -227.45% |
| 2020 Q3 | -330.52 Million USD | -9.57% |
| 2020 Q4 | -327.25 Million USD | 0.99% |
| 2020 FY | -327.25 Million USD | -251.66% |
| 2020 Q2 | -301.66 Million USD | 1.01% |
| 2019 Q3 | -95.99 Million USD | -42.42% |
| 2019 FY | -93.06 Million USD | 11.1% |
| 2019 Q2 | -67.39 Million USD | 1.67% |
| 2019 Q1 | -68.54 Million USD | 34.52% |
| 2019 Q4 | -93.06 Million USD | 3.05% |
| 2018 Q1 | -77.63 Million USD | -19.09% |
| 2018 FY | -104.68 Million USD | -60.57% |
| 2018 Q4 | -104.68 Million USD | 0.34% |
| 2018 Q3 | -105.04 Million USD | -35.3% |
| 2018 Q2 | -77.63 Million USD | 0.0% |
| 2017 Q1 | -63.01 Million USD | -14.34% |
| 2017 FY | -65.19 Million USD | -16.41% |
| 2017 Q4 | -65.19 Million USD | 0.0% |
| 2017 Q3 | -65.19 Million USD | -3.46% |
| 2017 Q2 | -63.01 Million USD | 0.0% |
| 2016 Q1 | -66.1 Million USD | 49.07% |
| 2016 FY | -56 Million USD | 56.85% |
| 2016 Q4 | -55.1 Million USD | 1.6% |
| 2016 Q3 | -56 Million USD | 15.28% |
| 2016 Q2 | -66.1 Million USD | 0.0% |
| 2015 Q3 | -129.79 Million USD | 40.45% |
| 2015 FY | -129.79 Million USD | 38.78% |
| 2015 Q4 | -129.79 Million USD | 0.0% |
| 2015 Q2 | -217.97 Million USD | 0.0% |
| 2015 Q1 | -217.97 Million USD | -2.81% |
| 2014 Q4 | -212.01 Million USD | -285.39% |
| 2014 Q3 | -55.01 Million USD | 0.0% |
| 2014 Q1 | 8.88 Million USD | 0.0% |
| 2014 FY | -212.01 Million USD | -7180.63% |
| 2013 FY | -2.91 Million USD | 69.01% |
| 2012 FY | -9.39 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -12763029.771% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 3060.093% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 490.711% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -66880.611% |
| Rebus Holdings, Inc. | 305 Thousand USD | 54918.689% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2552.016% |
| Qrons Inc. | 351.42 Thousand USD | 47676.595% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 26964.825% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 484.945% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -819171.854% |
| Skye Bioscience, Inc. | -5.72 Million USD | -2822.315% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1160.693% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4160.127% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 41706.922% |
| SQZ Biotechnologies Company | -36.23 Million USD | -361.386% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 7556.718% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 18132.736% |
| Mesoblast Limited | 55.85 Million USD | 399.324% |
| Marizyme, Inc. | 18.56 Million USD | 1000.408% |
| Genus plc | 190.6 Million USD | 187.721% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 7578.066% |
| Pharming Group N.V. | 109.8 Million USD | 252.269% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 19536.065% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 13873.676% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 24687.794% |
| ContraFect Corporation | -6.02 Million USD | -2674.593% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 124281.701% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 14570.556% |
| IMV Inc. | 7.67 Million USD | 2279.735% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3138.898% |
| MultiCell Technologies, Inc. | 90.04 USD | 185692014.705% |
| ONE Bio Corp. | 9.04 Million USD | 1949.517% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -22679.566% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1391.495% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 12322.262% |
| Q BioMed Inc. | 4.06 Million USD | 4218.145% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 647.218% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 16691.679% |
| Biomind Labs Inc. | 711.4 Thousand USD | 23602.464% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 376.15% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 8462.392% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1405.554% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 46581.054% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 119693.86% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 841681.517% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 7693.026% |
| GB Sciences, Inc. | 1.74 Million USD | 9668.79% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -90872.751% |
| HST Global, Inc. | 96.79 Thousand USD | 172836.665% |
| CSL Limited | 10.52 Billion USD | 101.588% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 81178.185% |
| Halberd Corporation | 144.72 Thousand USD | 115630.573% |
| Enzolytics Inc. | 981.65 Thousand USD | 17132.138% |
| Agentix Corp. | 37.63 Thousand USD | 444406.556% |
| Resverlogix Corp. | 6.45 Million USD | 2691.8% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -24740.251% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 91.759% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -255.647% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2464.555% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 6272.786% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1791.388% |
| AVAX Technologies, Inc. | -5.9 Million USD | -2732.308% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1661437.44% |
| Genscript Biotech Corporation | -1.06 Billion USD | 84.247% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 83518.316% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 7107.318% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 101733.953% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -912647.025% |
| Kadimastem Ltd | -253.1 Thousand USD | -65959.138% |
| Helix BioMedix, Inc. | -2.57 Million USD | -6405.639% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 924.605% |
| BioStem Technologies, Inc. | 4.47 Million USD | 3838.743% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 83177.603% |
| LadRx Corporation | -2.03 Million USD | -8110.142% |
| Cell Source, Inc. | 9.23 Million USD | 1911.065% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 26423.313% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 26423.313% |
| NovAccess Global Inc. | 2.17 Million USD | 7774.991% |
| Affymax, Inc. | -5.59 Million USD | -2887.261% |
| Itoco Inc. | 228.3 Thousand USD | 73334.051% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 123048.915% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3472.947% |
| Mobile Lads Corp. | 484.23 Thousand USD | 34628.284% |
| CytoDyn Inc. | 20.26 Million USD | 925.175% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -25841785.626% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1803858.422% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2269.698% |
| SYBLEU INC | 473.71 Thousand USD | 35394.925% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 3851.316% |
| International Stem Cell Corporation | 2.59 Million USD | 6555.483% |
| Bioxytran, Inc. | 1.89 Million USD | 8904.875% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 267988.1% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 7766.422% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 4968.87% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 2054.835% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 21740.627% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -13275.76% |
| Neutra Corp. | 52.18 Thousand USD | 320480.555% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -6617.437% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -68169.309% |
| IXICO plc | -4.44 Million USD | -3661.812% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1364.823% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 404.82% |
| CSL Limited | 10.52 Billion USD | 101.588% |
| Cellectis S.A. | -43.81 Million USD | -281.564% |